Sahara Shoko, Kinoshita Teruhisa, Amano Tomomi, Ishida Misa, Yamakita Takashi, Takimoto Norio, Oka Keisuke
Department of Pharmacy, Kariya Toyota General Hospital, Kariya, Japan.
Department of Clinical Laboratory, Kariya Toyota General Hospital, Kariya, Japan.
Nagoya J Med Sci. 2024 Aug;86(3):524-530. doi: 10.18999/nagjms.86.3.524.
This is the first case report of decubitus infection and bacteremia due to (). A patient in his 70s with pre-existing diabetes mellitus was admitted with decubitus infection, and tazobactam/piperacillin treatment was initiated. Tazobactam/piperacillin-resistant was detected in the blood and decubitus site cultures. The antimicrobial treatment was changed to clindamycin and cefmetazole. Antimicrobial therapy was administered for 28 days. The patient was transferred to a convalescent hospital. occasionally causes infection in immunocompromised patients with underlying diseases, such as diabetes. An appropriate evaluation by culture test is important for diagnosis, treatment, and recurrence prevention. Tazobactam/piperacillin is often used in the treatment of multi-bacterial infections such as decubitus infections. may be resistant to tazobactam/piperacillin, and this possibility should be taken into account when administering treatment.
这是首例因（）导致褥疮感染和菌血症的病例报告。一名患有糖尿病的70多岁患者因褥疮感染入院，并开始使用他唑巴坦/哌拉西林治疗。在血液和褥疮部位培养物中检测到对他唑巴坦/哌拉西林耐药的（）。抗菌治疗改为克林霉素和头孢美唑。抗菌治疗持续了28天。患者被转至康复医院。（）偶尔会在患有潜在疾病（如糖尿病）的免疫功能低下患者中引起感染。通过培养测试进行适当评估对于诊断、治疗和预防复发很重要。他唑巴坦/哌拉西林常用于治疗褥疮感染等多细菌感染。（）可能对他唑巴坦/哌拉西林耐药，在进行治疗时应考虑到这种可能性。
